Stefan Aebi
Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial.
Zander T, Pabst T, Schär S, Aebi S, Mey U, Novak U, Lerch E, Rhyner Agocs G, Goede J, Maniecka Z, Hayoz S, Rüfer A, Renner C, Driessen C. Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial. Leukemia 2023; 37:699-701.
Jan 12, 2023Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial.
Jan 12, 2023Leukemia 2023; 37:699-701
Zander Thilo, Pabst Thomas, Schär Sämi, Aebi Stefan, Mey Ulrich J M, Novak Urban, Lerch Erika, Rhyner Agocs Gaëlle, Goede Jeroen, Maniecka Zuzanna, Hayoz Stefanie, Rüfer Axel, Renner Christoph, Driessen Christoph
Clinical Implementation of Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland.
Begré U, Jörger M, Aebi S, Amstutz U, Largiadèr C. Clinical Implementation of Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland. Front Pharmacol 2022; 13:885259.
May 18, 2022Clinical Implementation of Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland.
May 18, 2022Front Pharmacol 2022; 13:885259
Begré Ursina B M, Jörger Markus, Aebi Stefan, Amstutz Ursula, Largiadèr Carlo R
Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy
Hamzic S, Aebi S, Jörger M, Montemurro M, Ansari M, Amstutz U, Largiadèr C. Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy. Swiss Med Wkly 2020; 150:w20375.
Nov 24, 2020Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy
Nov 24, 2020Swiss Med Wkly 2020; 150:w20375
Hamzic Seid, Aebi Stefan, Jörger Markus, Montemurro Michael, Ansari Marc, Amstutz Ursula, Largiadèr Carlo
Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis
Hamzic S, Amstutz U, López-Fernández L, García-González X, Schellens J, Meulendijks D, Thomlinson I, Palles C, Aebi S, Jörger M, Froehlich T, Kummer D, Largiadèr C. Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis. Pharmacol Res 2019; 152:104594.
Dec 12, 2019Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis
Dec 12, 2019Pharmacol Res 2019; 152:104594
Hamzic Seid, Amstutz Ursula, López-Fernández Luis A, García-González Xandra, Schellens Jan H M, Meulendijks Didier, Thomlinson Ian, Palles Claire, Aebi Stefan, Jörger Markus, Froehlich Tanja K, Kummer Dominic, Largiadèr Carlo R
Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data
Schmid S, Zaman K, Weder P, von Moos R, Thürlimann B, Rochlitz C, Pestalozzi B, Pagani O, Oehlschlegel C, Nolè F, Munzone E, Mamot C, Goldhirsch A, Aebi S, Klingbiel D, Ruhstaller T. Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data. BMC cancer 2019; 19:902.
Sep 10, 2019Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data
Sep 10, 2019BMC cancer 2019; 19:902
Schmid Sabine, Zaman Khalil, Weder Patrik, von Moos Roger, Thürlimann Beat, Rochlitz Christoph, Pestalozzi Bernhard, Pagani Olivia, Oehlschlegel Christian, Nolè Franco, Munzone Elisabetta, Mamot Christoph, Goldhirsch Aron, Aebi Stefan, Klingbiel Dirk, Ruhstaller Thomas
Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial
Wapnir I, Gelber S, Coates A, Gelber R, Rastogi P, Regan M, Wolmark N, Aebi S, International Breast Cancer Study Group, NRG Oncology, GEICAM Spanish Breast Cancer Group, BOOG Dutch Breast Cancer Trialists' Group, Geyer C, Mamounas E, Thürlimann B, Price K, Anderson S, Robidoux A, Martín M, Nortier J, Paterson A, Rimawi M, Láng I, Baena-Cañada J, Breast International Group. Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. J Clin Oncol 2018; 36:1073-1079.
Feb 14, 2018Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial
Feb 14, 2018J Clin Oncol 2018; 36:1073-1079
Wapnir Irene L, Gelber Shari, Coates Alan S, Gelber Richard D, Rastogi Priya, Regan Meredith M, Wolmark Norman, Aebi Stefan, International Breast Cancer Study Group, NRG Oncology, GEICAM Spanish Breast Cancer Group, BOOG Dutch Breast Cancer Trialists' Group, Geyer Charles E, Mamounas Eleftherios P, Thürlimann Beat, Price Karen N, Anderson Stewart J, Robidoux Andre, Martín Miguel, Nortier Johan W R, Paterson Alexander H G, Rimawi Mothaffar F, Láng István, Baena-Cañada José Manuel, Breast International Group
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
Colleoni M, Di Lauro V, Gombos A, Ruhstaller T, Burstein H, Ribi K, Bernhard J, Viale G, Maibach R, Rabaglio-Poretti M, Gelber R, Coates A, Di Leo A, Regan M, Goldhirsch A, O'Reilly S, Müller B, Marth C, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Hitre E, Graas M, Simoncini E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, SOLE Investigators. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2017; 19:127-138.
Nov 17, 2017Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
Nov 17, 2017Lancet Oncol 2017; 19:127-138
Colleoni Marco, Di Lauro Vincenzo, Gombos Andrea, Ruhstaller Thomas, Burstein Harold, Ribi Karin, Bernhard Jürg, Viale Giuseppe, Maibach Rudolf, Rabaglio-Poretti Manuela, Gelber Richard D, Coates Alan S, Di Leo Angelo, Regan Meredith M, Goldhirsch Aron, O'Reilly Seamus, Müller Bettina, Marth Christian, Luo Weixiu, Karlsson Per, Chirgwin Jacquie, Aebi Stefan, Jerusalem Guy, Neven Patrick, Hitre Erika, Graas Marie-Pascale, Simoncini Edda, Kamby Claus, Thompson Alastair, Loibl Sibylle, Gavilá Joaquín, Kuroi Katsumasa, SOLE Investigators
Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)
Pestalozzi B, Novak U, Nussbaum C, Seifert B, Bigler M, Bize V, Vilei S, Rageth C, Aebi S, Borner M, Buser K, Tausch C, Dedes K, Rochlitz C, Zimmermann S, von Moos R, Winterhalder R, Ruhstaller T, Mueller A. Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10). BMC cancer 2017; 17:265.
Apr 13, 2017Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)
Apr 13, 2017BMC cancer 2017; 17:265
Pestalozzi Bernhard C, Novak Urban, Nussbaum Catrina Uhlmann, Seifert Bettina, Bigler Martin, Bize Vincent, Vilei Simona Berardi, Rageth Christoph, Aebi Stefan, Borner Markus, Buser Katharina, Tausch Christoph, Dedes Konstantin J, Rochlitz Christoph, Zimmermann Stefan, von Moos Roger, Winterhalder Ralph, Ruhstaller Thomas, Mueller Andreas
Dihydropyrimidinase and β-ureidopropionase gene variation and severe fluoropyrimidine-related toxicity.
Kummer D, Froehlich T, Joerger M, Aebi S, Sistonen J, Amstutz U, Largiadèr C. Dihydropyrimidinase and β-ureidopropionase gene variation and severe fluoropyrimidine-related toxicity. Pharmacogenomics 2015; 16:1367-77.
Aug 5, 2015Dihydropyrimidinase and β-ureidopropionase gene variation and severe fluoropyrimidine-related toxicity.
Aug 5, 2015Pharmacogenomics 2015; 16:1367-77
Kummer Dominic, Froehlich Tanja K, Joerger Markus, Aebi Stefan, Sistonen Johanna, Amstutz Ursula, Largiadèr Carlo R
Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity
Froehlich T, Amstutz U, Aebi S, Jörger M, Largiadèr C. Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity. Int J Cancer 2014; 136:730-9.
Jun 27, 2014Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity
Jun 27, 2014Int J Cancer 2014; 136:730-9
Froehlich Tanja K, Amstutz Ursula, Aebi Stefan, Jörger Markus, Largiadèr Carlo R
Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences
Decensi A, Coates A, Goldhirsch A, Gelber R, Price K, Johansson H, Zaman K, Schönenberger A, Debled M, Campone M, Monnier A, Tondini C, McIntosh C, Thürlimann B, Guerrieri-Gonzaga A, Sun Z, Aebi S. Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences. Breast Cancer Res Treat 2014; 144:321-9.
Feb 1, 2014Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences
Feb 1, 2014Breast Cancer Res Treat 2014; 144:321-9
Decensi Andrea, Coates Alan S, Goldhirsch Aron, Gelber Richard D, Price Karen N, Johansson Harriet, Zaman Khalil, Schönenberger Astrid, Debled Marc, Campone Mario, Monnier Alain, Tondini Carlo, McIntosh Christina, Thürlimann Beat, Guerrieri-Gonzaga Aliana, Sun Zhuoxin, Aebi Stefan
Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial
Aebi S, Mamounas E, Geyer C, Price K, Coates A, Gelber R, Rastogi P, Wolmark N, Wapnir I, Murray E, Thürlimann B, Cañada J, Gelber S, Anderson S, Láng I, Robidoux A, Martín M, Nortier J, Paterson A, Rimawi M, CALOR investigators. Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. Lancet Oncol 2014; 15:156-63.
Jan 16, 2014Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial
Jan 16, 2014Lancet Oncol 2014; 15:156-63
Aebi Stefan, Mamounas Eleftherios P, Geyer Charles E, Price Karen N, Coates Alan S, Gelber Richard D, Rastogi Priya, Wolmark Norman, Wapnir Irene L, Murray Elizabeth, Thürlimann Beat, Cañada José Manuel Baena, Gelber Shari, Anderson Stewart J, Láng István, Robidoux Andre, Martín Miguel, Nortier Johan W R, Paterson Alexander H G, Rimawi Mothaffar F, CALOR investigators
Optimal sequence of tamoxifen and aromatase inhibitors to prevent bone loss
Zaman K, Thürlimann B, Aebi S. Optimal sequence of tamoxifen and aromatase inhibitors to prevent bone loss. J Clin Oncol 2013; 31:3440-1.
Aug 5, 2013Optimal sequence of tamoxifen and aromatase inhibitors to prevent bone loss
Aug 5, 2013J Clin Oncol 2013; 31:3440-1
Zaman Khalil, Thürlimann Beat, Aebi Stefan
Trastuzumab Treatment beyond Progression in Advanced Breast Cancer: Patterns of Care in Six Swiss Breast Cancer Centers
Huober J, Widmer I, von Rohr L, Müller A, von Moos R, Güth U, Aebi S, Rochlitz C, Baumann M, Thürlimann B. Trastuzumab Treatment beyond Progression in Advanced Breast Cancer: Patterns of Care in Six Swiss Breast Cancer Centers. Oncology 2011; 81:160-166.
Oct 28, 2011Trastuzumab Treatment beyond Progression in Advanced Breast Cancer: Patterns of Care in Six Swiss Breast Cancer Centers
Oct 28, 2011Oncology 2011; 81:160-166
Huober Jens, Widmer Isabelle, von Rohr Lukas, Müller Andreas, von Moos Roger, Güth Uwe, Aebi Stefan, Rochlitz Christoph, Baumann Michael, Thürlimann Beat
Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue
Antonov J, Aebi S, Altermatt H, Viale G, Giobbie-Hurder A, Thürlimann B, Oberli A, Baltzer A, Wirapati P, Delorenzi M, Popovici V, Jaggi R. Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue. BMC cancer 2010; 10:37.
Feb 9, 2010Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue
Feb 9, 2010BMC cancer 2010; 10:37
Antonov Janine, Aebi Stefan, Altermatt Hans Jorg, Viale Giuseppe, Giobbie-Hurder Anita, Thürlimann Beat, Oberli Andrea, Baltzer Anna, Wirapati Pratyaksha, Delorenzi Mauro, Popovici Vlad, Jaggi Rolf
Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII
Bernhard J, Coates A, Goldhirsch A, Price K, Thürlimann B, Aebi S, Collins J, Murray E, Forbes J, Gelber R, Hürny C, Castiglione-Gertsch M, Zahrieh D, International Breast Cancer Study Group Trial VIII. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII. JCO 2007; 25:263-70.
Jan 20, 2007Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII
Jan 20, 2007JCO 2007; 25:263-70
Bernhard Jürg, Coates Alan S, Goldhirsch Aron, Price Karen N, Thürlimann Beat, Aebi Stefan, Collins John, Murray Elizabeth, Forbes John F, Gelber Richard D, Hürny Christoph, Castiglione-Gertsch Monica, Zahrieh David, International Breast Cancer Study Group Trial VIII
Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial
Thürlimann B, Rochlitz C, Aebi S, Perey L, Pagani O, Ballabeni P, Senn I, Köberle D, Hess D, Goldhirsch A. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial. Breast Cancer Res Treat 2004; 85:247-54.
Jun 1, 2004Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial
Jun 1, 2004Breast Cancer Res Treat 2004; 85:247-54
Thürlimann Beat, Rochlitz Christoph, Aebi Stefan, Perey Lucien, Pagani Olivia, Ballabeni Pierluigi, Senn Isabella, Köberle Dieter, Hess Dagmar, Goldhirsch Aron